JP2023547999A5 - - Google Patents
Info
- Publication number
- JP2023547999A5 JP2023547999A5 JP2023520041A JP2023520041A JP2023547999A5 JP 2023547999 A5 JP2023547999 A5 JP 2023547999A5 JP 2023520041 A JP2023520041 A JP 2023520041A JP 2023520041 A JP2023520041 A JP 2023520041A JP 2023547999 A5 JP2023547999 A5 JP 2023547999A5
- Authority
- JP
- Japan
- Prior art keywords
- component
- agent
- cancer treatment
- pharmaceutical product
- product according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063086216P | 2020-10-01 | 2020-10-01 | |
| US63/086,216 | 2020-10-01 | ||
| PCT/US2021/052271 WO2022072293A2 (en) | 2020-10-01 | 2021-09-28 | Methods and compositions for synergistic uptake and retention of small molecule ligands |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023547999A JP2023547999A (ja) | 2023-11-15 |
| JP2023547999A5 true JP2023547999A5 (https=) | 2024-09-26 |
Family
ID=80950778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023520041A Pending JP2023547999A (ja) | 2020-10-01 | 2021-09-28 | 低分子リガンドの相乗的取り込み及び保持のための方法及び組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240000979A1 (https=) |
| EP (1) | EP4221764A4 (https=) |
| JP (1) | JP2023547999A (https=) |
| AU (1) | AU2021352378A1 (https=) |
| CA (1) | CA3194600A1 (https=) |
| IL (1) | IL301842A (https=) |
| WO (1) | WO2022072293A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018204477A1 (en) | 2017-05-02 | 2018-11-08 | Cornell University | Methods and reagents for tumor targeting with greater efficacy and less toxicity |
| US20240000979A1 (en) * | 2020-10-01 | 2024-01-04 | Cornell University | Methods and compositions for synergistic uptake and retention of small molecule ligands |
| CA3258344A1 (en) | 2022-06-07 | 2023-12-14 | Actinium Pharmaceuticals, Inc. | CHELETARIANS AND BIFUNCTIONAL CONJUGATES |
| WO2025029946A1 (en) | 2023-07-31 | 2025-02-06 | Curium Us Llc | [177lu] lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007044616A2 (en) * | 2005-10-06 | 2007-04-19 | Xencor, Inc. | Optimized anti-cd30 antibodies |
| WO2018204477A1 (en) * | 2017-05-02 | 2018-11-08 | Cornell University | Methods and reagents for tumor targeting with greater efficacy and less toxicity |
| US20240000979A1 (en) * | 2020-10-01 | 2024-01-04 | Cornell University | Methods and compositions for synergistic uptake and retention of small molecule ligands |
-
2021
- 2021-09-28 US US18/247,427 patent/US20240000979A1/en active Pending
- 2021-09-28 WO PCT/US2021/052271 patent/WO2022072293A2/en not_active Ceased
- 2021-09-28 JP JP2023520041A patent/JP2023547999A/ja active Pending
- 2021-09-28 EP EP21876268.0A patent/EP4221764A4/en active Pending
- 2021-09-28 CA CA3194600A patent/CA3194600A1/en active Pending
- 2021-09-28 AU AU2021352378A patent/AU2021352378A1/en active Pending
- 2021-09-28 IL IL301842A patent/IL301842A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023547999A5 (https=) | ||
| Arnaldez et al. | Targeting the insulin growth factor receptor 1 | |
| Colcher et al. | Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72. 3) in patients with carcinoma | |
| JP2020518639A5 (https=) | ||
| CN104717966B (zh) | 用于癌症靶向治疗和预防癌症复发的含有基于血红蛋白的氧载体的药物组合物 | |
| Agarwala et al. | Interferons in melanoma | |
| US20220143227A1 (en) | Method of Treatment of Neuroendocrine Tumors That Over-Express Somatostatatin Receptors | |
| US9125835B2 (en) | Synergistic combinations to reduce particle dose for targeted treatment of cancer and its metastases | |
| JP2023547998A5 (https=) | ||
| JP2011526626A5 (https=) | ||
| JP7373998B2 (ja) | 有効性がより大きくかつ毒性がより少ない腫瘍標的指向方法及び試薬 | |
| WO2021182573A1 (ja) | 癌の治療及び／又は予防のための医薬品 | |
| Order et al. | Radiolabeled antibodies: results and potential in cancer therapy | |
| Shah et al. | Targeted radionuclide therapies for pancreatic cancer | |
| AU2023389426A1 (en) | Method of treating prostate cancer | |
| Shimizu et al. | Development of tissue factor-targeted liposomes for effective drug delivery to stroma-rich tumors | |
| Willhauck et al. | Functional sodium iodide symporter expression in breast cancer xenografts in vivo after systemic treatment with retinoic acid and dexamethasone | |
| De Bonis et al. | Radioimmunotherapy for high-grade glioma | |
| Fujiuchi et al. | Suramin inhibits the growth of non-small-cell lung cancer cells that express the epidermal growth factor receptor | |
| US20240288425A1 (en) | Selection of patients for combination therapy | |
| EP4719377A1 (en) | Methods of using alternating electric fields and checkpoint inhibitors | |
| Heskamp et al. | Alpha-versus beta-emitting radionuclides for pretargeted radioimmunotherapy of CEA-expressing human colon cancer xenografts | |
| EP1091757A2 (en) | Alpha emitting constructs and uses thereof | |
| Li et al. | 131I-recombinant human EGF has antitumor effects against MCF-7 human breast cancer xenografts with low levels of EGFR | |
| Pantaleo et al. | PET detection of epidermal growth factor receptor in colorectal cancer: a real predictor of response to cetuximab treatment? |